TY - JOUR
T1 - Cloning of an isoform of integrin-linked kinase (ILK) that is upregulated in HT-144 melanoma cells following TGF-β1 stimulation
AU - Janji, Bassam
AU - Melchior, Chantal
AU - Vallar, Laurent
AU - Kieffer, Nelly
N1 - Funding Information:
This work was supported by grants from Centre de Recherche Public – Santé (CRP – Santé, Luxembourg), CNRS (France), Fondation Luxembourgeoise contre le Cancer (Luxembourg) and EC Biomed-Project BMH4-CT98-3517. B Janji is a recipient of a fellowship from the MinisteÁ re de la Culture, de l'Enseignement Supérieur et de la Recherche, Luxembourg. The data presented were obtained by B Janji as part of his doctoral thesis submitted to the University Pierre et Marie Curie, Paris, France.
PY - 2000/6/22
Y1 - 2000/6/22
N2 - We have shown previously that integrin-linked kinase (ILK) is upregulated in human HT-144 melanoma cells following TGF-β1 stimulation. Using mRNA from TGF-β1 stimulated HT-144 tells and reverse transcriptase polymerase chain reaction, we have isolated a cDNA encoding a protein highly homologous to ILK. Sequencing of the full-length 1359 base pair cDNA and polypeptide translation revealed that this protein, designated ILK-2, differs from the known ILK (hereafter called ILK-1) by only four amino acids, while the cDNA sequence diverges by 102 nucleotides, thus excluding that ILK-2 is an allelic variant of ILK-1. Expression of ILK-2 mRNA was observed in metastatic human HT-144 melanoma and HT-1080 fibrosarcoma cell lines, but not in normal human tissues. Moreover, stimulation of HT-144 cells with TGF-β1, but not with EGF, PDGF-AB or insulin, induced a selective overexpression of ILK-2 mRNA as compared to ILK-1 mRNA. Bacterially-expressed GST/ILK-2 autophosphorylated and labeled myelin basic protein as well as a recombinant GST/β3 integrin cytoplasmic tail peptide. Transfection of either ILK-2 or ILK-1 cDNA into the non-metastatic melanoma cell line SK-Mel-2, expressing exclusively ILK-1, induced anchorage independent cell growth and cell proliferation, as demonstrated by growth in soft agar. Our data provide evidence that ILK-2 is a new isoform of ILK-1 that is expressed in some highly invasive tumor cell lines but not in normal adult human tissues and whose expression is regulated by TGF-β1.
AB - We have shown previously that integrin-linked kinase (ILK) is upregulated in human HT-144 melanoma cells following TGF-β1 stimulation. Using mRNA from TGF-β1 stimulated HT-144 tells and reverse transcriptase polymerase chain reaction, we have isolated a cDNA encoding a protein highly homologous to ILK. Sequencing of the full-length 1359 base pair cDNA and polypeptide translation revealed that this protein, designated ILK-2, differs from the known ILK (hereafter called ILK-1) by only four amino acids, while the cDNA sequence diverges by 102 nucleotides, thus excluding that ILK-2 is an allelic variant of ILK-1. Expression of ILK-2 mRNA was observed in metastatic human HT-144 melanoma and HT-1080 fibrosarcoma cell lines, but not in normal human tissues. Moreover, stimulation of HT-144 cells with TGF-β1, but not with EGF, PDGF-AB or insulin, induced a selective overexpression of ILK-2 mRNA as compared to ILK-1 mRNA. Bacterially-expressed GST/ILK-2 autophosphorylated and labeled myelin basic protein as well as a recombinant GST/β3 integrin cytoplasmic tail peptide. Transfection of either ILK-2 or ILK-1 cDNA into the non-metastatic melanoma cell line SK-Mel-2, expressing exclusively ILK-1, induced anchorage independent cell growth and cell proliferation, as demonstrated by growth in soft agar. Our data provide evidence that ILK-2 is a new isoform of ILK-1 that is expressed in some highly invasive tumor cell lines but not in normal adult human tissues and whose expression is regulated by TGF-β1.
KW - Integrin
KW - Integrin-linked kinase
KW - Melanoma phosphorylation
KW - TGF-β
KW - cDNA sequence
UR - http://www.scopus.com/inward/record.url?scp=0034702253&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/10871859
U2 - 10.1038/sj.onc.1203640
DO - 10.1038/sj.onc.1203640
M3 - Article
C2 - 10871859
AN - SCOPUS:0034702253
SN - 0950-9232
VL - 19
SP - 3069
EP - 3077
JO - Oncogene
JF - Oncogene
IS - 27
ER -